About Me
More info forI am a member of the Translational Therapeutics Program at the OSUCCC – James, where the overall goal of my research is to evaluate the contribution of solute carriers to cancer drug-induced toxicity profiles, particularly peripheral neuropathy. In addition, I aim to identify chemical inhibitors of critical transporters and explore novel preclinical and clinical strategies to ameliorate the incidence and severity of debilitating side effects of cancer drugs.
My research interests include drug development and translational cancer pharmacology, particularly the development of transport modulators that can be used in conjunction with neurotoxic chemotherapy to understand drug transporter regulation mechanisms. By doing so, we can then determine the role of drug transporters on anticancer agent-induced inter-individual pharmacokinetic variability, antitumor efficacy and drug-to-drug interaction.
My work has been published in peer-reviewed journals, including Journal of Clinical Investigation, Nature Communications, Clinical Cancer Research, Clinical Pharmacology & Therapeutics, and Cancer Research.
Academic Office & Contact Information
More info forAcademic Office:
Riffe Building R0442
496 W 12th Ave
Columbus, Ohio 43210-1214Phone:
614-247-6203Email:
hu.1333@osu.eduPublications
More info forAugust 29, 2024Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen.
Drabison T, Boeckman M, Yang Y, Huang KM, de Bruijn P, Nepal MR, Silvaroli JA, Chowdhury AT, Eisenmann ED, Cheng X, Pabla N, Mathijssen RHJ, Baker SD, Hu S, Sparreboom A, Talebi Z
Cancer Res Commun
April 2, 2024Quantification of the aromatase inhibitor letrozole and its carbinol metabolite in mouse plasma by UHPLC-MS/MS.
Taheri H, Jin Y, Ahmed E, Hu P, Li Y, Sparreboom A, Hu S
J Chromatogr B Biomed Sci Appl
March 16, 2024Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
Buck SAJ, Talebi Z, Drabison T, Jin Y, Gibson AA, Hu P, de Bruijn P, de Ridder CMA, Stuurman D, Hu S, van Weerden WM, Koolen SLW, de Wit R, Sparreboom A, Mathijssen RHJ, Eisenmann ED
Int J Cancer
December 8, 2023Vincristine Disposition and Neurotoxicity are Unchanged in Humanized CYP3A5 Mice.
Li Y, Kazuki Y, Drabison T, Kobayashi K, Fujita KI, Xu Y, Jin Y, Ahmed E, Li J, Eisenmann ED, Baker SD, Cavaletti G, Sparreboom A, Hu S
Drug Metab Dispos
November 1, 2022Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity.
Nepal MR, Taheri H, Li Y, Talebi Z, Uddin ME, Jin Y, DiGiacomo DF, Gibson AA, Lustberg MB, Hu S, Sparreboom A
Cancer Res Commun
October 12, 2022Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B.
Garrison DA, Jin Y, Talebi Z, Hu S, Sparreboom A, Baker SD, Eisenmann ED
Molecules
September 13, 2022A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug-Drug Interaction Liabilities.
Li Y, Jin Y, Taheri H, Schmidt KT, Gibson AA, Buck SAJ, Eisenmann ED, Mathijssen RHJ, Figg WD, Baker SD, Sparreboom A, Hu S
Pharmaceutics
August 27, 2022Determination of the endogenous OATP1B biomarkers glycochenodeoxycholate-3-sulfate and chenodeoxycholate-24-glucuronide in human and mouse plasma by a validated UHPLC-MS/MS method.
Jin Y, Li Y, Eisenmann ED, Figg WD, Baker SD, Sparreboom A, Hu S
J Chromatogr B Biomed Sci Appl
May 11, 2022Transporters and Toxicity: Insights from the International Transporter Consortium Workshop 4.
Hafey MJ, Aleksunes LM, Bridges CC, Brouwer KR, Chien HC, Leslie EM, Hu S, Li Y, Shen J, Sparreboom A, Sprowl J, Tweedie D, Lai Y
Clin Pharmacol Ther
April 7, 2022Regulation of Drug Transport Proteins - From Mechanisms to Clinical Impact; A White Paper on Behalf of the ITC.
Brouwer KLR, Evers R, Hayden E, Hu S, Li CY, Meyer Zu Schwabedissen HE, Neuhoff S, Oswald S, Piquette-Miller M, Saran C, Sjöstedt N, Sprowl J, Stahl SH, Yue W
Clin Pharmacol Ther
April 5, 2022Influence of Tyrosine Kinase Inhibition on OATP1B3-mediated Uptake.
Hove VN, Anderson K, Hayden ER, Pasquariello KZ, Gibson AA, Shen S, Qu J, Jin Y, Miecznikowski JC, Hu S, Sprowl JA
Mol Pharmacol
November 25, 2021In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors.
Uddin ME, Talebi Z, Chen S, Jin Y, Gibson AA, Noonan AM, Cheng X, Hu S, Sparreboom A
Pharmaceutics
September 10, 2021Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation.
Li Y, Talebi Z, Chen X, Sparreboom A, Hu S
Molecules
July 8, 2021Contribution of Membrane Transporters to Chemotherapy-Induced Cardiotoxicity.
Uddin ME, Moseley A, Hu S, Sparreboom A
Basic Clin Pharmacol Toxicol
June 21, 2021Imaging-Based Characterization of a Slco2b1(-/-) Mouse Model Using [11C]Erlotinib and [99mTc]Mebrofenin as Probe Substrates.
Marie S, Hernández-Lozano I, Breuil L, Truillet C, Hu S, Sparreboom A, Tournier N, Langer O
Pharmaceutics
March 4, 2021Regulation of OATP1B1 function by tyrosine kinase-mediated phosphorylation.
Hayden E, Chen M, Pasquariello KZ, Gibson AA, Petti JJ, Shen S, Qu J, Ong SS, Chen T, Jin Y, Uddin ME, Huang KM, Paz A, Sparreboom A, Hu S, Sprowl JA
Clin Cancer Res
February 21, 2021Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies.
Jin Y, Li Y, Uddin ME, Sparreboom A, Hu S
J Chromatogr B Analyt Technol Biomed Life Sci
February 12, 2021Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy.
Li Y, Lustberg MB, Hu S
Cancers (Basel)
February 2, 2021Targeting OCT3 attenuates doxorubicin-induced cardiac injury.
Huang KM, Zavorka Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A
Proc Natl Acad Sci U S A
January 1, 2021Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1.
Uddin ME, Garrison DA, Kim K, Jin Y, Eisenmann ED, Huang KM, Gibson AA, Hu Z, Sparreboom A, Hu S
Front Pharmacol
September 9, 2020DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Buelow DR, Anderson JT, Pounds SB, Shi L, Lamba JK, Hu S, Gibson AA, Goodwin EA, Sparreboom A, Baker SD
Clin Transl Sci
August 7, 2020Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.
Anderson JT, Huang KM, Lustberg MB, Sparreboom A, Hu S
Rev Physiol Biochem Pharmacol
June 2, 2020Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice.
Huang KM, Leblanc AF, Uddin ME, Kim JY, Chen M, Eisenmann ED, Gibson A, Li Y, Hong KW, DiGiacomo D, Xia SH, Alberti P, Chiorazzi A, Housley SN, Cope TC, Sprowl JA, Wang J, Loprinzi CL, Noonan A, Lustberg M, Cavaletti G, Pabla N, Hu S, Sparreboom A
J Clin Invest
April 10, 2020Role of SLC transporters in toxicity induced by anticancer drugs.
Huang KM, Uddin ME, DiGiacomo D, Lustberg MB, Hu S, Sparreboom A
Expert Opin Drug Metab Toxicol